
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Apertura Gene Therapy
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Apertura Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners
Details : Galibra Neuroscience and Emugen Therapeutics will utilize Apertura's human transferrin receptor 1 capsid (TfR1 CapX) for their central nervous system (CNS) programs.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Apertura Gene Therapy
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Contact Us!